Pioneer Institute study finds IRA discourages non-opioid drug innovation
A study from a US-based public policy research firm has highlighted that the US Inflation Reduction Act (IRA) is likely…
All articles by Jenna Philpott
Jenna Philpott
Jenna Philpott is a trainee healthcare and pharmaceutical reporter. Coming from a scientific background, Jenna has expertise in biochemistry, genetics and cancer science. Jenna previously wrote freelance articles focused on oncology and healthcare.
-
-
Inflation Reduction Act to have knock on effect on R&D, say biotech experts
Discussions surrounding the Inflation Reduction Act (IRA) are heating up as the 2026 effect date gets closer. Speakers at the…
-
Life science SMEs “heading out of the funding winter”
After what has been deemed a “funding winter” for life science SMEs, building a strong data package to attract larger…
-
Social prescribing: friend or foe for pharma?
As the number of patients being diagnosed with mental health conditions, diabetes, and other chronic conditions increases, more primary care…
-
Targeting mouth cancer with light-activated drugs
With two in five patients with oral cancer dying within five years and 95% of patients requiring life-altering surgery, finding…
-
Hyundai to advance cancer study plans for niclosamide-based drug
Hyundai Bioscience is advancing its niclosamide-based cancer candidate into Phase I/IIa trials for several hard-to-treat cancers following a successful preclinical…
-
Vertex’s pain drug suzetrigine advances in FDA approval process
Vertex Pharmaceuticals’ suzetrigine, previously named VX-548, is steadily advancing along its rolling submission approval pathway okayed by the US Food…
-
Chemomab touts study confirming CCL24 link to systemic sclerosis severity
Clinical-stage biotech Chemomab Therapeutics has announced the publication of a study highlighting that high serum CCL24 levels are linked to…
-
Lexeo wins fast track designation for Friedreich’s ataxia gene therapy
Clinical-stage genetic medicine company Lexeo Therapeutics has won fast track designation from the US Food and Drug Administration (FDA) for…
-
Two major breakthroughs in Fragile X Syndrome treatments
Spinogenix has received approval from the US Food and Drug Administration (FDA) for a Phase II clinical trial of SPG601…